Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02835534
Recruitment Status : Unknown
Verified July 2016 by Guangzhou Recomgen Biotech Co., Ltd..
Recruitment status was:  Active, not recruiting
First Posted : July 18, 2016
Last Update Posted : July 18, 2016
Sponsor:
Collaborators:
Chinese Academy of Medical Sciences, Fuwai Hospital
Peking University
Information provided by (Responsible Party):
Guangzhou Recomgen Biotech Co., Ltd.

Brief Summary:
This study is aiming to test the hypothesis that efficacy of rhTNK-tPA was not inferior to rt-PA with respect to the 30-day MACCE rates after fibrinolytic therapy for STEMI patients. It is a multicenter, randomized, open, parallel, active-controlled, non-inferiority trial.

Condition or disease Intervention/treatment Phase
Acute ST Elevation Myocardial Infarction Drug: rhTNK-tPA Drug: alteplase Phase 4

Detailed Description:

The study includes screening and baseline, randomization & intervention, in-hospital visit, at 30±3 days visit after fibrinolytic therapy.

Following an initial eligibility screening assessment, all eligible patients who have signed the informed consent will be randomly assigned by an interactive Web-based central system for fibrinolytic therapy with either rhTNK-tPA or rt-PA. The standard care should be given to all patients except for the study interventions.

Prior to fibrinolytic administration, enoxaparin (30-mg intravenous) or Un- Fractionated Heparin (maximum 4000U, intravenous) should be administered, combined with antiplatelet therapy consisted of both clopidogrel and aspirin in a 300-mg loading dose followed by routine dosage.

Successful reperfusion according to the clinical evidence (EKG) should be assessed after fibrinolytic therapy.TIMI flow should be assessed for those patients with 24 hours coronary angiography.

MACCE and bleeding events should be followed up and documented during the study until 30 days after fibrinolytic therap. An independent adjudication committee will judge the major endpoint events.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 6200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute ST Elevation Myocardial Infarction(STEMI): a Multi-center, Randomized, Open, Parallel, Non-inferiority, Active Controlled Trial
Study Start Date : May 2016
Estimated Primary Completion Date : January 2019
Estimated Study Completion Date : January 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Alteplase

Arm Intervention/treatment
Experimental: rhTNK-tPA
rhTNK-tPA; Dose:16mg; Mode of admin: Single bolus Dose:50mg; Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
Drug: rhTNK-tPA
Dose:16mg; Mode of admin: Single bolus Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
Other Name: Recombinant Human TNK Tissue-type Plasminogen Activator

Active Comparator: rt-PA
Drug:alteplase;Dose:50mg; Mode of admin: administered as an 8-mg initial IV bolus followed by an infusion of 42 mg over the next 90 minutes Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
Drug: alteplase
Dose:50mg; Mode of admin: administered as an 8-mg initial IV bolus followed by an infusion of 42 mg over the next 90 minutes Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
Other Name: rt-PA




Primary Outcome Measures :
  1. The rate of MACCE(Major Adverse Cardiovascular and Cerebrovascular Events) [ Time Frame: within 30 days after the start of fibrinolytic therapy ]
    MACCE composited of total death, non-fatal recurrent MI, non-fatal stroke (ischemic and Hemorrhage), PCI for failed reperfusion and PCI for reocclusion


Secondary Outcome Measures :
  1. The proportion of patients with TIMI grade 3 flow in the infarct-related artery after therapy (Limited to the subgroup for coronary angiography within 24 hours after therapy ) [ Time Frame: within 24 hours after therapy ]
  2. The rate of successful reperfusion with clinical evidences [ Time Frame: within 24 hours of fibrinolytic therapy ]
  3. The in-hospital MACCE [ Time Frame: during hospitalization (from the date of admission to the date of discharge, assessed up to 1 month) ]
  4. The in-hospital and 30-day all-cause mortality [ Time Frame: during hospitalization (from the date of admission to the date of discharge, assessed up to 1 month) and 30 days after the start of study interventions ]
  5. The in-hospital and 30-day cardiac deaths [ Time Frame: during hospitalization (from the date of admission to the date of discharge) and 30 days after the start of study interventions, assessed up to 1 month ]
  6. The in-hospital recurrent MI [ Time Frame: during hospitalization (from the date of admission to the date of discharge, assessed up to 1 month) ]
  7. The 30-day revascularization [ Time Frame: 30 days after the start of therapy ]
  8. The in-hospital intracranial hemorrhage (ICH) [ Time Frame: during hospitalization (from the date of admission to the date of discharge, assessed up to 1 month) ]
  9. The in-hospital major GI bleeding events [ Time Frame: during hospitalization (from the date of admission to the date of discharge, assessed up to 1 month) ]
  10. The in-hospital total bleeding events [ Time Frame: during hospitalization (from the date of admission to the date of discharge, assessed up to 1 month) ]

Other Outcome Measures:
  1. The frequency and severity of AEs [ Time Frame: during hospitalization (from the date of admission to the date of discharge, assessed up to 1 month) ]
  2. Medical cost within the initial hospitalization [ Time Frame: from the date of admission to the date of discharge, assessed up to 1 month ]
  3. The frequency of re-hospitalizations and emergency room visits [ Time Frame: at 30 days after therapy ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Diagnosis of acute STEMI(meet with both conditions):

    • Ischemic chest pain ≥30mins in duration
    • ST elevation ≥0.1 mV in two or more limb ECG leads or ≥0.2 mV in two or more contiguous precordial leads
  2. Onset of continuous ischemic symptoms of STEMI ≤6 hours prior to randomisation
  3. Anticipated Delay to Performing Primary PCI >60mins,or time from hospital arrival to to balloon inflation >90mins
  4. Signed Informed consent received prior to participation the study

Exclusion Criteria:

  1. Non-ST-segment-elevation myocardial infarction or unstable angina
  2. Reinfacrtion
  3. Cardiacgenic shock
  4. Suspected aortic dissection
  5. New left bundle branch block in ECG
  6. Absolute and relative contraindications for Fibrinolytic Therapy in STEMI(referred from 2015 China STEMI Management Guideline):

    • Severe uncontrolled hypertension (unresponsive to emergency Therapy,BPs > 180 mmHg and/or BPd > 110 mmHg)
    • Any prior ICH,stroke with unknown cause, Ischemic stroke within 3 months
    • Known structural cerebral vascular lesion, malignant intracranial neoplasm
    • Active bleeding, or bleeding diathesis, active peptic ulcer
    • Significant closed-head or facial trauma within 3 months
    • Intracranial or intraspinal surgery within 2 months
    • Recent internal bleeding within 4 weeks
    • Major surgery within 3 weeks, or Traumatic
    • Prolonged cardiopulmonary resuscitation (>10 minutes)
    • Noncompressible vascular punctures within 2 weeks
    • Current use of anticoagulant therapy
  7. Current or with a history of significant diseases:

    • Damage to the central nervous system
    • Severe renal or hepatic dysfunction, blood system diseases,
    • Present with cardiac rupture evidence
    • Acute pericarditis,Subacute bacterial endocarditis, Septic thrombophlebitis or occluded AV cannula at seriously infected site
    • Malignancy
    • High likelihood of left heart thrombus, e.g., mitral stenosis with atrial fibrillation
    • Diabetic hemorrhagic retinopathy or other hemorrhagic ophthalmic conditions
    • History of PCI or coronary artery bypass graft(CABG)within 1 month
  8. Administration of fibrinlytic therapy prior to participation
  9. Weight below 50 kg
  10. Known current histroy of fall-down accident
  11. Any other unfavourable conditions for participation:

    • Known participation in other clinical trials
    • Known to allergic to rhTNK-tPA or tPA or relevant vehicle
    • Pregnancy or lactation
    • Mental disorder
    • Present with any unsuitable conditions for participation or completion of the study at the discretion of their treating physician

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02835534


Locations
Layout table for location information
China, Guangdong
Guangzhou Recomgen Biotech Co., Ltd.
Guangzhou, Guangdong, China, 510530
Sponsors and Collaborators
Guangzhou Recomgen Biotech Co., Ltd.
Chinese Academy of Medical Sciences, Fuwai Hospital
Peking University
Investigators
Layout table for investigator information
Principal Investigator: Shubin Qiaos, MD Chinese Academy of Medical Sciences, Fuwai Hospital
Study Director: Qin Yang, MD Guangzhou Recomgen Biotech Co., Ltd.
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Guangzhou Recomgen Biotech Co., Ltd.
ClinicalTrials.gov Identifier: NCT02835534    
Other Study ID Numbers: CP-2015-01
First Posted: July 18, 2016    Key Record Dates
Last Update Posted: July 18, 2016
Last Verified: July 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Guangzhou Recomgen Biotech Co., Ltd.:
acute ST elevation myocardial infarction
Additional relevant MeSH terms:
Layout table for MeSH terms
Myocardial Infarction
ST Elevation Myocardial Infarction
Infarction
Ischemia
Pathologic Processes
Necrosis
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Tissue Plasminogen Activator
Plasminogen
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action